Xenical (orlistat) / Roche, GSK - LARVOL DELTA

Weight Loss Aid in an Exposed Population (clinicaltrials.gov) - P1/2 | N=120 | Not yet recruiting | Sponsor: Emory University

New P1/2 trial

Weight Loss Aid in an Exposed Population (clinicaltrials.gov) - P1/2 | N=120 | Recruiting | Sponsor: Emory University | Not yet recruiting ➔ Recruiting

Enrollment open

Weight Loss Aid in an Exposed Population (clinicaltrials.gov) - P4 | N=100 | Completed | Sponsor: Emory University | Active, not recruiting ➔ Completed

Trial completion

Weight Loss Aid in an Exposed Population (clinicaltrials.gov) - P4 | N=100 | Active, not recruiting | Sponsor: Emory University | Recruiting ➔ Active, not recruiting | Phase classification: P1/2 ➔ P4 | Trial completion date: Apr 2023 ➔ Jul 2022

Enrollment closed • Phase classification • Trial completion date

Weight Loss Aid in an Exposed Population (clinicaltrials.gov) - P1/2 | N=120 | Recruiting | Sponsor: Emory University | Trial completion date: Apr 2022 ➔ Apr 2023 | Trial primary completion date: Apr 2021 ➔ Apr 2022

Trial completion date • Trial primary completion date

The Association Between Glucagon-Like Peptide-1 Receptor Agonists Use and Liver Outcomes in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Without Diabetes (ACG 2026) - "A cohort of adults with MASLD and without diabetes who initiated GLP-1RA were compared to those who initiated orlistat, phentermine-topiramate, or naltrexone-bupropion (non GLP-1RA anti-obesity medication users). After matching, 9056 pairs of GLP-1RA users and non GLP-1RA anti-obesity medication users were analyzed. GLP-1RA use was associated with a significantly reduced risk of decompensated cirrhosis events (HR 0.692, 95% CI 0.496-0.965, p=0.029) within 5 years. Specifically, GLP-1RA use was associated with lower risks of ascites-related complications (HR 0.538, 95% CI 0.367-0.790, p=0.001)."

Clinical • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Coronary Artery Disease • Diabetes • Fibrosis • Gastroenterology • Genetic Disorders • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Hypertension • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Obesity • Renal Disease • Solid Tumor • Type 2 Diabetes Mellitus • Vascular Neurology

A Preventable Path to Dialysis: Oxalate Nephropathy in Exocrine Pancreatic Insufficiency (ACG 2026) - "He denied prior surgery, excess dietary oxalate/ascorbic acid intake, or orlistat use...This case highlights the importance of prompt pancreatic enzyme replacement and calcium supplementation in such patients to reduce enteric hyperoxaluria, prevent tubular injury, and potentially avert ESRD. Figure: Image 1: Renal biopsy showing intratubular deposition of calcium oxalate crystals under light microscopy (Hematoxylin Eosin stain)"

Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Fibrosis • Immunology • Metabolic Disorders • Nephrology • Pancreatitis • Renal Disease

A novel dual-epitope ELISA reveals heterogeneity of circulating lipoprotein lipase: distinguishing intact LPL from total LPL. (PubMed, Clin Chim Acta) - "The F1A/R23B ELISA distinguishes an LPL species retaining both antibody-defined terminal regions from conventional total LPL immunoreactivity. These findings demonstrate biochemical heterogeneity of circulating LPL under the specific experimental and clinical conditions examined in this study. Prospective studies are required to establish the incremental clinical value of intact LPL measurement."

Heterogeneity • Journal • Pancreatitis • LPL

Research on Weight Management of Hospitalized Mental Patients (ChiCTR) - P=N/A | N=90 | Recruiting | Sponsor: The 984th Hospital of the Joint Logistic Support Force of the People's Liberation Army of China; The 984th Hospital of the Joint Logistic Support Forc

New trial

Age-Related Variation in Flavonoid Composition, Human Pancreatic Lipase Inhibition, and Preliminary Brine Shrimp Lethality of Rhododendron adamsii Leaves and Sagan Dali Tea. (PubMed, Foods) - "The highest antilipase potency of sagan dali tea was recorded in first-year leaves (IC50 30.65-33.47 μg/mL vs. orlistat 35.28 μg/mL)...In summary, the age of R. adamsii leaves is a critical parameter determining phytocomponent concentrations and associated bioactivity while consistently maintaining low brine shrimp lethality under the tested conditions. These findings provide a biochemical basis for further research into the optimal use of R. adamsii leaf material."

Journal • STAT3

MSMEI_4050 modulates resistance to the antitubercular drug rifampicin in Mycolicibacterium smegmatis. (PubMed, J Glob Antimicrob Resist) - "MSMEI_4050 expression is associated with rifampicin resistance; further studies are needed to understand the role of MSMEI_4050 in the mechanism underlying rifampicin resistance."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Comparative midterm outcomes of contemporary revascularization strategies for acute lower limb ischemia: a retrospective cohort study. (PubMed, Front Cardiovasc Med) - "Acute lower limb ischaemia (ALLI) is a vascular emergency associated with high morbidity and mortality...Hybrid strategies demonstrate intermediate results. These findings support individualized treatment selection, but definitive causal inferences are limited by the non - randomized design and potential residual confounding."

Journal • Retrospective data • Acute Kidney Injury • Cardiovascular • Nephrology • Renal Disease

Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis. (PubMed, Front Pharmacol) - "Comparisons with metformin and orlistat helped distinguish drug-related signals from disease-related signals. Additionally, we identified signals for suicidal ideation. Future studies are needed to evaluate for causal relationships."

Adverse events • Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Pancreatitis • Psychiatry • Suicidal Ideation • Type 2 Diabetes Mellitus

Oral Obesity Medicines in the Era of Cardiovascular-Kidney-Metabolic Syndrome (CKM): Beyond Weight Loss Toward Disease Modification. (PubMed, Drug Des Devel Ther) - "This review summarizes currently approved oral obesity medications, including first generation agents (orlistat, phentermine/topiramate, and naltrexone/bupropion) and second generation incretin-based therapies (oral semaglutide and orforglipron), within the context of CKM syndrome. Orforglipron represents the first non-peptide oral glucagon-like peptide-1 receptor agonist and offers simplified administration with promising metabolic efficacy; however, cardiovascular, kidney, heart failure, and arrhythmia outcome data are still awaited. Collectively, the role of oral obesity pharmacotherapy is evolving from weight management alone toward comprehensive CKM care."

Journal • Review • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Diabetes • Genetic Disorders • Heart Failure • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

Effect of Electroacupuncture on Central Obesity and Fatty Liver in Postmenopausal Women (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: Cairo University | Not yet recruiting ➔ Completed | Trial completion date: Jun 2026 ➔ Sep 2026 | Trial primary completion date: Jun 2026 ➔ Sep 2026

Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Effect of Electroacupuncture on Central Obesity and Fatty Liver in Postmenopausal Women (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Cairo University

New trial • Genetic Disorders • Obesity

Sonication pretreatment enhances the yield of Murraya koenigii essential oil and the bioactivity of its nanoemulsion. (PubMed, Nat Prod Res) - "MKEONE exhibited LPL inhibition (IC50 158 ± 0.005 µL). Both samples upregulated PRDM16 expression in 3T3-L1 adipocytes by 3.64- and 2.73-fold, respectively, comparable to Orlistat (p > 0.05) under the tested conditions."

Journal • PRDM16

Digestive Lipases as Therapeutic Targets in Obesity: From Orlistat to Next-Generation Inhibitors. (PubMed, Biochimie) - "Emphasis is placed on the critical design principles required for next-generation inhibitors, including strict luminal confinement, high selectivity for digestive lipases, and controlled, reversible inhibition to improve tolerability. By bridging biochemical insights with pharmacological challenges, this review outlines a roadmap for the development of safer, more effective lipid-targeted therapies to combat obesity."

Journal • Review • Genetic Disorders • Metabolic Disorders • Obesity

The Effect of Xenical on Weight and Risk Factors (clinicaltrials.gov) - P4 | N=25 | Completed | Sponsor: University of British Columbia | Recruiting ➔ Completed

Trial completion • Cardiovascular • Genetic Disorders • Obesity

Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review. (PubMed, Diabetes Metab Syndr Obes) - "The review encompassed glucagon-like peptide-1 receptor agonists (GLP-1 RA), including semaglutide, liraglutide, exenatide, and orforglipron; multi-receptor incretin agonists, including tirzepatide, retatrutide, and survodutide; amylin-based combination therapy (cagrilintide plus semaglutide); established non-incretin AOMs (orlistat, phentermine, phentermine/topiramate, and naltrexone/bupropion); microbiome-targeted therapies; and nutraceutical-based interventions. Overall, incretin-based therapies currently provide the greatest weight-loss benefit, although evidence for several emerging pharmacotherapies, microbiome-targeted therapies, and nutraceutical-based interventions remains limited. Further well-designed comparative trials, mechanistic studies, and long-term real-world investigations are needed to better establish the durability, safety, and clinical applicability of emerging AOMs."

Journal • Review • Genetic Disorders • Obesity

OOTER: Orlistat Overcoming Third-generation EGFR-TKI Resistance (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: Ping Peng

New P2 trial • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phocaeicola dorei YGMCC0564 attenuates HFD-induced glycolipid metabolic disorders in association with remodeling of the gut microbiota and bile acid profiles. (PubMed, Front Microbiol) - "Current pharmacotherapies such as orlistat and metformin show clear efficacy but are associated with long-term tolerability concerns. Oral YGMCC0564 produced no obvious adverse effects in acute and subchronic tests in immunodeficient and normal mice. These findings indicate that YGMCC0564 may modulate FXR-FGF15/19 and GPBAR1/TGR5 signaling via the gut environment, thereby potentially contributing to its hypoglycemic and hypolipidemic effects."

Journal • Diabetes • Dyslipidemia • Metabolic Disorders • FGF19

Akkermansia muciniphila HHAKKα Prevents High-Fat Diet-Induced Obesity in Mice via Gut Microbiota Modulation and Regulation of Hepatic Lipid Metabolism. (PubMed, FASEB J) - "Results demonstrated that HHAKKα significantly inhibited weight gain (5.76 g vs. 10.79 g in HFD group), with efficacy comparable to orlistat...Molecular analysis revealed that HHAKKα regulated hepatic lipid metabolism by inhibiting FASN expression and upregulating PGC-1α. These findings suggest that A. muciniphila HHAKKα ameliorates HFD-induced obesity through a multi-faceted mechanism involving gut microbiota modulation, SCFA production enhancement, inflammation suppression, and hepatic lipid metabolism regulation, highlighting its therapeutic potential for obesity management."

Journal • Preclinical • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity • FASN • IL1B • TNFA

Orlistat: a comprehensive review of a lipase inhibitor from obesity management to emerging oncological applications. (PubMed, Front Pharmacol) - "This discovery has spurred investigation into its potential as an anti-neoplastic agent, with studies demonstrating its ability to induce apoptosis, arrest cell cycle progression, and synergize with immunotherapy in cancer models. This review provides a comprehensive analysis of Orlistat, covering its molecular mechanisms, clinical efficacy and safety in diverse populations, impact on metabolic health, and the exciting, yet nascent, evidence for its repurposing in oncology."

Journal • Review • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Metabolic Disorders • Obesity • Oncology • Type 2 Diabetes Mellitus • FASN

Economic evaluations of antiobesity medications: A systematic literature review. (PubMed, Br J Clin Pharmacol) - "We systematically reviewed full economic evaluations of approved antiobesity medications in adults with overweight or obesity, including tirzepatide, semaglutide, liraglutide, naltrexone/bupropion, orlistat, phentermine and phentermine/topiramate. Direct comparative economic evidence between newer agents remains limited. Long-term real-world data and clearer distinctions between cost-effectiveness and affordability are needed to inform policy decisions."

HEOR • Journal • Review • Genetic Disorders • Obesity